BIVI: Bezisterim showed significant symptom improvement in Long COVID patients with high baseline burden
Topline results from a Phase 2 trial show bezisterim improved neurological symptoms in Long COVID patients with high baseline fatigue, cognitive impairment, or post-exertional malaise, with a safety profile similar to placebo. No endpoints reached significance in the overall population, but signifi…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.